Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

181. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review

The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review Bustamante M, Stollman N Authors' objectives To perform a systematic review of all randomised controlled trials (RCTs), performed between 1990 and 1998, evaluating proton-pump inhibitors (PPIs) in patients with acute ulcer bleeding in the upper (...) that well-designed double-blinded RCTs using initial endoscopic treatment, where appropriate, with stratification by stigmata of recent haemorrhage, be undertaken. Continuous infusion may be more efficacious than intermittent dosing, but this too requires confirmation. Bibliographic details Bustamante M, Stollman N. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. Journal of Clinical Gastroenterology 2000; 30(1): 7-13 PubMedID Indexing Status Subject indexing

2000 DARE.

182. Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease

Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer (...) disease Habu Y, Kiyota K, Inokuchi H, Sugano Y, Ko K, Waki S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Proton pump inhibitor based dual and triple therapy regimens for Helicobacter pylori eradication in peptic ulcer disease

1999 NHS Economic Evaluation Database.

183. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection (...) : a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole Huang J Q, Hunt R H Authors' objectives To examine the effect of seven-day triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole for Helicobacter pylori (H pylori) eradication and evaluate which dose of clarithromycin is more effective for eradicating H pylori infection. Searching Published articles and abstracts in the English language were sought

1999 DARE.

184. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis

Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Harris R A, Kuppermann M, Richter J E (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Proton pump inhibitors and Histamine-2 receptor antagonists in the prevention of recurrences of erosive reflux esophagitis. Type of intervention Secondary prevention. Economic study

1997 NHS Economic Evaluation Database.

185. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition

, Richter J E. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. American Journal of Medicine 1997; 102(1): 78-88 PubMedID Indexing Status Subject indexing assigned by NLM MeSH 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents /economics /therapeutic use; Cost-Benefit Analysis; Esophagitis, Peptic /economics /prevention & Humans; Lansoprazole; Omeprazole /analogs & Proton Pump Inhibitors; Quality of Life; Recurrence (...) Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition Harris R A, Kuppermann M, Richter J E Record Status This is a critical abstract of an economic evaluation that meets

1997 NHS Economic Evaluation Database.

186. Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2

Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2 Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy (...) as compared to H2-receptor antagonists: meta-analysis of parallel-group studies] Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2-receptor antagonists: meta-analysis of parallel-group studies] Holtmann G, Layer P, Goebell H Authors' objectives The authors aimed to assess the available parallel-group

1996 DARE.